Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.



Insurance Coverage

SHINGRIX is covered for more than 95% of US commercial medical benefit enrollees and 100% of Medicare Part D enrollees in the US as of October 2018.

Commercial medical benefit enrollees

  • Primarily people <65 years
  • Out of pocket costs are likely to be limited if vaccine is administered in network for members of plans implemented after passage of the Affordable Care Act (ACA)
    • Individual costs may vary

Medicare Part D enrollees

  • Primarily people ≥65 years
  • Per Medicare policy, shingles vaccines are only covered in Part D plans, not in Part B
    • Part D covered vaccinations are typically administered at a retail site of care (pharmacy)
  • Out of pocket costs vary due to different plan benefit designs, special beneficiary status and individual drug utilization

For more information, please contact the GSK Vaccines Reimbursement Support Center.

The GSK Vaccines Reimbursement Support Center is a resource for physicians, physician office staff, and pharmacists to help address questions about billing, coding, and reimbursement for GSK vaccines.

GSK Vaccines Reimbursement Support Center contact information:

Phone: 1-855-636-8291
Fax: 1-877-683-1329
Monday – Friday 8:00 AM-8:00 PM ET

Visit GSK Vaccines Reimbursement Support Center for more information.


SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
  • Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
  • SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

All trademarks are the property of their respective owners.